Global Pharmaceutical Intermediate CDMO Market Research Report 2025

Publication ID:

PB504259419

Publication Date:

May 2, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Pharmaceutical Intermediate CDMO was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Pharmaceutical Intermediate CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Pharmaceutical Intermediate CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Pharmaceutical Intermediate CDMO in Pharmaceutical Company is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Pharmaceutical Intermediate CDMO include Cambrex, WR Grace, Esteve Qu铆mica, AGC Pharma Chemicals, Evonik, CordenPharma, Otsuka Chemical, Wavelength, KBI Biopharma, Chengda Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical Intermediate CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical Intermediate CDMO.
The Pharmaceutical Intermediate CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pharmaceutical Intermediate CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmaceutical Intermediate CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cambrex
WR Grace
Esteve Qu铆mica
AGC Pharma Chemicals
Evonik
CordenPharma
Otsuka Chemical
Wavelength
KBI Biopharma
Chengda Pharmaceuticals
Apeloa Pharmaceutical
Xi'an Manareco New Materials
Shenzhen Sungening Bio-technology
Chengdu D-innovation Pharmaceutical
Huateng Pharma
Segment by Type
Small Molecule Cdmo
Macromolecular Cdmo
Segment by Application
Pharmaceutical Company
Biotechnology Company
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceutical Intermediate CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical Intermediate CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Small Molecule Cdmo
1.2.3 Macromolecular Cdmo
1.3 Market by Application
1.3.1 Global Pharmaceutical Intermediate CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical Intermediate CDMO Market Perspective (2020-2031)
2.2 Global Pharmaceutical Intermediate CDMO Growth Trends by Region
2.2.1 Global Pharmaceutical Intermediate CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Pharmaceutical Intermediate CDMO Historic Market Size by Region (2020-2025)
2.2.3 Pharmaceutical Intermediate CDMO Forecasted Market Size by Region (2026-2031)
2.3 Pharmaceutical Intermediate CDMO Market Dynamics
2.3.1 Pharmaceutical Intermediate CDMO Industry Trends
2.3.2 Pharmaceutical Intermediate CDMO Market Drivers
2.3.3 Pharmaceutical Intermediate CDMO Market Challenges
2.3.4 Pharmaceutical Intermediate CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical Intermediate CDMO Players by Revenue
3.1.1 Global Top Pharmaceutical Intermediate CDMO Players by Revenue (2020-2025)
3.1.2 Global Pharmaceutical Intermediate CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Pharmaceutical Intermediate CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Pharmaceutical Intermediate CDMO Revenue
3.4 Global Pharmaceutical Intermediate CDMO Market Concentration Ratio
3.4.1 Global Pharmaceutical Intermediate CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical Intermediate CDMO Revenue in 2024
3.5 Global Key Players of Pharmaceutical Intermediate CDMO Head office and Area Served
3.6 Global Key Players of Pharmaceutical Intermediate CDMO, Product and Application
3.7 Global Key Players of Pharmaceutical Intermediate CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical Intermediate CDMO Breakdown Data by Type
4.1 Global Pharmaceutical Intermediate CDMO Historic Market Size by Type (2020-2025)
4.2 Global Pharmaceutical Intermediate CDMO Forecasted Market Size by Type (2026-2031)
5 Pharmaceutical Intermediate CDMO Breakdown Data by Application
5.1 Global Pharmaceutical Intermediate CDMO Historic Market Size by Application (2020-2025)
5.2 Global Pharmaceutical Intermediate CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Pharmaceutical Intermediate CDMO Market Size (2020-2031)
6.2 North America Pharmaceutical Intermediate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Pharmaceutical Intermediate CDMO Market Size by Country (2020-2025)
6.4 North America Pharmaceutical Intermediate CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical Intermediate CDMO Market Size (2020-2031)
7.2 Europe Pharmaceutical Intermediate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Pharmaceutical Intermediate CDMO Market Size by Country (2020-2025)
7.4 Europe Pharmaceutical Intermediate CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical Intermediate CDMO Market Size (2020-2031)
8.2 Asia-Pacific Pharmaceutical Intermediate CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Pharmaceutical Intermediate CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Pharmaceutical Intermediate CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical Intermediate CDMO Market Size (2020-2031)
9.2 Latin America Pharmaceutical Intermediate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Pharmaceutical Intermediate CDMO Market Size by Country (2020-2025)
9.4 Latin America Pharmaceutical Intermediate CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical Intermediate CDMO Market Size (2020-2031)
10.2 Middle East & Africa Pharmaceutical Intermediate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Pharmaceutical Intermediate CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Pharmaceutical Intermediate CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cambrex
11.1.1 Cambrex Company Details
11.1.2 Cambrex Business Overview
11.1.3 Cambrex Pharmaceutical Intermediate CDMO Introduction
11.1.4 Cambrex Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.1.5 Cambrex Recent Development
11.2 WR Grace
11.2.1 WR Grace Company Details
11.2.2 WR Grace Business Overview
11.2.3 WR Grace Pharmaceutical Intermediate CDMO Introduction
11.2.4 WR Grace Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.2.5 WR Grace Recent Development
11.3 Esteve Qu铆mica
11.3.1 Esteve Qu铆mica Company Details
11.3.2 Esteve Qu铆mica Business Overview
11.3.3 Esteve Qu铆mica Pharmaceutical Intermediate CDMO Introduction
11.3.4 Esteve Qu铆mica Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.3.5 Esteve Qu铆mica Recent Development
11.4 AGC Pharma Chemicals
11.4.1 AGC Pharma Chemicals Company Details
11.4.2 AGC Pharma Chemicals Business Overview
11.4.3 AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Introduction
11.4.4 AGC Pharma Chemicals Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.4.5 AGC Pharma Chemicals Recent Development
11.5 Evonik
11.5.1 Evonik Company Details
11.5.2 Evonik Business Overview
11.5.3 Evonik Pharmaceutical Intermediate CDMO Introduction
11.5.4 Evonik Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.5.5 Evonik Recent Development
11.6 CordenPharma
11.6.1 CordenPharma Company Details
11.6.2 CordenPharma Business Overview
11.6.3 CordenPharma Pharmaceutical Intermediate CDMO Introduction
11.6.4 CordenPharma Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.6.5 CordenPharma Recent Development
11.7 Otsuka Chemical
11.7.1 Otsuka Chemical Company Details
11.7.2 Otsuka Chemical Business Overview
11.7.3 Otsuka Chemical Pharmaceutical Intermediate CDMO Introduction
11.7.4 Otsuka Chemical Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.7.5 Otsuka Chemical Recent Development
11.8 Wavelength
11.8.1 Wavelength Company Details
11.8.2 Wavelength Business Overview
11.8.3 Wavelength Pharmaceutical Intermediate CDMO Introduction
11.8.4 Wavelength Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.8.5 Wavelength Recent Development
11.9 KBI Biopharma
11.9.1 KBI Biopharma Company Details
11.9.2 KBI Biopharma Business Overview
11.9.3 KBI Biopharma Pharmaceutical Intermediate CDMO Introduction
11.9.4 KBI Biopharma Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.9.5 KBI Biopharma Recent Development
11.10 Chengda Pharmaceuticals
11.10.1 Chengda Pharmaceuticals Company Details
11.10.2 Chengda Pharmaceuticals Business Overview
11.10.3 Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Introduction
11.10.4 Chengda Pharmaceuticals Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.10.5 Chengda Pharmaceuticals Recent Development
11.11 Apeloa Pharmaceutical
11.11.1 Apeloa Pharmaceutical Company Details
11.11.2 Apeloa Pharmaceutical Business Overview
11.11.3 Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Introduction
11.11.4 Apeloa Pharmaceutical Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.11.5 Apeloa Pharmaceutical Recent Development
11.12 Xi'an Manareco New Materials
11.12.1 Xi'an Manareco New Materials Company Details
11.12.2 Xi'an Manareco New Materials Business Overview
11.12.3 Xi'an Manareco New Materials Pharmaceutical Intermediate CDMO Introduction
11.12.4 Xi'an Manareco New Materials Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.12.5 Xi'an Manareco New Materials Recent Development
11.13 Shenzhen Sungening Bio-technology
11.13.1 Shenzhen Sungening Bio-technology Company Details
11.13.2 Shenzhen Sungening Bio-technology Business Overview
11.13.3 Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Introduction
11.13.4 Shenzhen Sungening Bio-technology Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.13.5 Shenzhen Sungening Bio-technology Recent Development
11.14 Chengdu D-innovation Pharmaceutical
11.14.1 Chengdu D-innovation Pharmaceutical Company Details
11.14.2 Chengdu D-innovation Pharmaceutical Business Overview
11.14.3 Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Introduction
11.14.4 Chengdu D-innovation Pharmaceutical Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.14.5 Chengdu D-innovation Pharmaceutical Recent Development
11.15 Huateng Pharma
11.15.1 Huateng Pharma Company Details
11.15.2 Huateng Pharma Business Overview
11.15.3 Huateng Pharma Pharmaceutical Intermediate CDMO Introduction
11.15.4 Huateng Pharma Revenue in Pharmaceutical Intermediate CDMO Business (2020-2025)
11.15.5 Huateng Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Cambrex
WR Grace
Esteve Qu铆mica
AGC Pharma Chemicals
Evonik
CordenPharma
Otsuka Chemical
Wavelength
KBI Biopharma
Chengda Pharmaceuticals
Apeloa Pharmaceutical
Xi'an Manareco New Materials
Shenzhen Sungening Bio-technology
Chengdu D-innovation Pharmaceutical
Huateng Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂